GlassScriptPhysician profile
Lawrence D Wolin
NPI 1982606836
$2,181.60
in general payments reported to CMS, 2019-2025
20 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $70.32 · 2021: $76.76 · 2022: $287 · 2023: $548 · 2024: $411 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $477.44 | 2020-2025 | Cequa |
| Allergan, INC. | $252.97 | 2019-2022 | |
| Abbvie INC. | $184.03 | 2022-2025 | |
| Alcon Vision LLC | $162.10 | 2022-2025 | Eysuvis, Rocklatan, Simbrinza |
| Harrow Eye, LLC | $157.93 | 2023-2025 | Vevye |
| Bausch & Lomb Americas INC. | $148.76 | 2023-2025 | Vyzulta, Alrex, Zylet |
| Novartis Pharmaceuticals Corporation | $132.71 | 2019-2023 | |
| Thea Pharma INC. | $123.38 | 2023-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $88.95 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $67.09 | 2019 | |
| Ocular Therapeutix, INC. | $60.44 | 2023 | Dextenza |
| Shire North American Group INC | $59.08 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.01 | 2019 | |
| Rayner Intraocular Lenses Limited | $52.94 | 2023-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Johnson & Johnson Surgical Vision, INC. | $44.35 | 2022-2023 | Tecnis Simplicity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $33.00 | 2019-2020 | |
| Glaukos Corporation | $25.09 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Beaver-Visitec International, INC. | $22.75 | 2023 | |
| Lensar, INC. | $19.47 | 2019 | |
| Biotissue Holdings INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Wolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.